Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2017
Iodine Symporter Targeting with 124I/131I TheranosticsJames Nagarajah, Marcel Janssen, Philipp Hetkamp, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 8, 2018
Current Treatment Strategies in Metastasized Differentiated Thyroid CancerMichael C Kreissl, Marcel J R Janssen, James Nagarajah
Thyroid : Official Journal of the American Thyroid Association|October 18, 2016
Serum Thyroglobulin Doubling Time in Progressive Thyroid CancerRonja Maria Rössing, Walter Jentzen, James Nagarajah, et al.
Nuclear Medicine Communications|March 9, 2018
Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activitiesMarcus Ruhlmann, Wilfried Sonnenschein, James Nagarajah, et al.
Clinical Nuclear Medicine|January 10, 2012
Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinomaFlorian Grabellus, James Nagarajah, Andreas Bockisch, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 13, 2019
The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancerManuel Weber, Ina Binse, James Nagarajah, et al.
Clinical Nuclear Medicine|February 8, 2012
Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imagingSandra Julia Rosenbaum-Krumme, Lutz Stefan Freudenberg, Walter Jentzen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 28, 2015
Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET StudyJames Nagarajah, Alan L Ho, R Michael Tuttle, et al.
Cancers|August 27, 2021
Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate CancerNicolai Mader, Daniel Groener, Nikolaos Tselis, et al.
European Urology Focus|March 26, 2022
Ferumoxtran-10-enhanced 3-T Magnetic Resonance Angiography of Pelvic Arteries: Initial ExperiencePatrik Zamecnik, Bas Israel, Jürgen Feuerstein, et al.
Pageof 10